

## Supporting information

### Transition Metal Complexes Bearing NHC Ligands Substituted with Secondary Polyfluoroalkyl Groups.

V. Kolaříková<sup>a</sup>, O. Šimůnek<sup>a</sup>, M. Rybáčková<sup>a</sup>, J. Cvačka<sup>b</sup>, A. Březinová<sup>b</sup> and J. Kvíčala<sup>\*a</sup>

<sup>a</sup> Department of Organic Chemistry, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic. E-mail: kvicalaj@vscht.cz.

<sup>b</sup> Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nám. 2, 166 10 Prague 6, Czech Republic.

#### Table of Content

S1	General procedures
S1	Syntheses
S3	Copies of <sup>1</sup> H, <sup>19</sup> F and <sup>13</sup> C NMR spectra

#### General Procedures

Temperature data were uncorrected. NMR spectra were recorded with a Varian MercuryPlus spectrometer or with an Agilent 400-MR DDR2 spectrometer. For the Varian MercuryPlus spectrometer, <sup>1</sup>H NMR spectra were recorded at 299.97 MHz, <sup>13</sup>C NMR spectra were recorded at 75.44 MHz using residual deuterated solvent signals as the internal standards, and <sup>19</sup>F NMR spectra were recorded at 282.23 MHz using CCl<sub>3</sub>F as the internal standard. For the Agilent 400-MR DDR2 spectrometer, <sup>1</sup>H NMR spectra were recorded at 399.94 MHz, <sup>13</sup>C NMR spectra were recorded at 100.58 MHz and <sup>19</sup>F NMR spectra were recorded at 376.29 MHz. Chemical shifts are given in parts per million, coupling constants in Hertz. Mass spectra (ESI, APCI) were measured with a LCQ Fleet (Finnigan) instrument and HRMS spectra (ESI, APCI, FAB) with a LTQ Orbitrap XL (Thermo Fisher Scientific) or ZAB-EQ (VG Analytical) instrument. Melting points were measured by Electrothermal IA 9100 instrument.

All reactions were performed in a dry inert atmosphere (Ar) in oven-dried flasks. In the reactions including ruthenium or palladium, solids were introduced into the reaction flasks in a glove box.

#### Syntheses

##### **2,2,3,3,4,4,5,5,6,6,7,7,7-Tridecafluoroheptane-1,1-diol (7).**

An oven-dried round-bottom flask was charged with aluminium powder (0.304 g, 11.2 mmol), lead(II) bromide (0.082 g, 0.22 mmol) and DMF (23 mL). Under a sonication, perfluorohexyl iodide (**6**, 5.00 g, 11.2 mmol) was added to the mixture dropwise. The resulting heterogeneous mixture was sonicated for 2 h and then poured into 10% hydrochloric acid (50 mL). The solids were filtered off and the filtrate was extracted with diethyl ether (3 × 50 mL), combined organic extracts were washed with water (3 × 30 mL) and dried with anhydrous MgSO<sub>4</sub>. The solvent was removed on a rotary vacuum evaporator (40 °C, 30 min, 65 kPa) and the crude product was purified by sublimation using a

Kugelrohr apparatus (110-130 °C, 101 kPa) yielding diol **7** (2.31 g, 56.3%, white powder). <sup>1</sup>H NMR (299.97 MHz, acetone-*d*<sub>6</sub>): δ 5.43 (t, <sup>3</sup>J<sub>H-F</sub> = 7.6 Hz, 1H, CH(OH)<sub>2</sub>), 6.40 (d, <sup>3</sup>J<sub>H-H</sub> = 7.3 Hz, 2H, CH(OH)<sub>2</sub>) ppm. <sup>19</sup>F NMR (282.23 MHz, acetone-*d*<sub>6</sub>): δ -80.6 (t, <sup>4</sup>J<sub>F-F</sub> = 10 Hz, 3F, CF<sub>3</sub>), -121.6 (bs, 2F, CF<sub>2</sub>), -121.9 (bs, 2F, CF<sub>2</sub>), -122.3 (bs, 2F, CF<sub>2</sub>), -125.7 (bs, 2F, CF<sub>2</sub>), -127.4 (bs, 2F, CF<sub>2</sub>) ppm.

**Attempted preparation of bis[1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-yl)-4,5-dihydroimidazol-2-ylidene]silver(I) bis(tetrafluoroborato)argentate (**22**).**

Imidazolium salt **21** (20 mg, 0,025 mmol), silver(I) oxide (3,2 mg, 0,014 mmol), powdered molecular sieves 4Å (25 mg) and acetonitrile (1.6 mL) were placed into a foil-covered flask. The reaction mixture was stirred for 48h at room temperature. Filtration and evaporation of solvent on a rotary vacuum evaporator (50 °C, 1 h, 8 kPa) yielded crude reaction mixture, which according to analysis with <sup>1</sup>H a <sup>19</sup>F NMR spectroscopy contained mainly starting imidazolium salt **21** with small amount of admixtures.

### Copies of $^1\text{H}$ , $^{19}\text{F}$ and $^{13}\text{C}$ NMR Spectra




Figure S1.  $^1\text{H}$  NMR spectrum, 299.97 MHz, acetone- $d_6$ , 2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoroheptane-1,1-diol (**7**).




Figure S2.  $^{19}\text{F}$  NMR spectrum, 282.23 MHz, acetone- $d_6$ , 2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoroheptane-1,1-diol (**7**).




Figure S3. <sup>1</sup>H NMR spectrum, 299.97 MHz, CDCl<sub>3</sub>, 2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoro-*N*-(4-methoxyphenyl)heptan-1-imine (**8**).




Figure S4. <sup>19</sup>F NMR spectrum, 282.23 MHz, CDCl<sub>3</sub>, 2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoro-*N*-(4-methoxyphenyl)heptan-1-imine (**8**).






Figure S7. <sup>19</sup>F NMR spectrum, 282.23 MHz, CDCl<sub>3</sub>, 4-methoxy-*N*-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-yl)aniline (**9**).




Figure S8. <sup>13</sup>C NMR spectrum, 75.44 MHz, CDCl<sub>3</sub>, 4-methoxy-*N*-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-yl)aniline (**9**).




Figure S9.  $^1\text{H}$  NMR spectrum, 299.97 MHz,  $\text{CDCl}_3$ , 2-methyl-*N*-(2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoroheptylidene)propane-2-sulfonamide (**11**).




Figure S10.  $^{19}\text{F}$  NMR spectrum, 282.23 MHz,  $\text{CDCl}_3$ , 2-methyl-*N*-(2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoroheptylidene)propane-2-sulfonamide (**11**).




Figure S11. <sup>13</sup>C NMR spectrum, 75.44 MHz, CDCl<sub>3</sub>, 2-methyl-N-(2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoroheptylidene)propane-2-sulfinamide (**11**).




Figure S12. <sup>1</sup>H NMR spectrum, 299.97 MHz, CDCl<sub>3</sub>, 2-methyl-N-(3,3,4,4,5,5,6,6,7,7,8,8-tridecafluorooctan-2-yl)propane-2-sulfinamide (**12**).






Figure S13.  $^{19}\text{F}$  NMR spectrum, 282.23 MHz,  $\text{CDCl}_3$ , 2-methyl-*N*-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-yl)propane-2-sulfonamide (**12**).




Figure S14.  $^{13}\text{C}$  NMR spectrum, 75.44 MHz,  $\text{CDCl}_3$ , 2-methyl-*N*-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-yl)propane-2-sulfonamide (**12**).




Figure S15.  $^1\text{H}$  NMR spectrum, 299.97 MHz,  $\text{CDCl}_3$ , 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-one (**14**).




Figure S16.  $^{19}\text{F}$  NMR spectrum, 282.23 MHz,  $\text{CDCl}_3$ , 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-one (**14**).




Figure S17.  $^1\text{H}$  NMR spectrum, 299.97 MHz,  $\text{CDCl}_3$ , *N*-benzyl-3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-imine (**15**).




Figure S18.  $^{19}\text{F}$  NMR spectrum, 282.23 MHz,  $\text{CDCl}_3$ , *N*-benzyl-3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-imine (**15**).




Figure S19. <sup>13</sup>C NMR spectrum, 75.44 MHz, CDCl<sub>3</sub>, *N*-benzyl-3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-imine (**15**).




Figure S20. <sup>1</sup>H NMR spectrum, 299.97 MHz, CDCl<sub>3</sub>, *N*-benzylidene-3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-amine (**16**).




Figure S21. <sup>19</sup>F NMR spectrum, 282.23 MHz, CDCl<sub>3</sub>, *N*-benzylidene-3,3,4,4,5,5,6,6,7,7,8,8-tridecafluorooctan-2-amine (**16**).




Figure S22. <sup>13</sup>C NMR spectrum, 75.44 MHz, CDCl<sub>3</sub>, *N*-benzylidene-3,3,4,4,5,5,6,6,7,7,8,8-tridecafluorooctan-2-amine (**16**).




Figure S23.  $^1\text{H}$  NMR spectrum, 299.97 MHz,  $\text{CD}_3\text{OD}$ , 3,3,4,4,5,5,6,6,7,7,8,8-tridecafluorooctan-2-ammonium chloride (**10.HCl**).




Figure S24.  $^{19}\text{F}$  NMR spectrum, 282.23 MHz,  $\text{CD}_3\text{OD}$ , 3,3,4,4,5,5,6,6,7,7,8,8-tridecafluorooctan-2-ammonium chloride (**10.HCl**).




Figure S25.  $^{13}\text{C}$  NMR spectrum, 282.23 MHz,  $\text{CD}_3\text{OD}$ , 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-ammonium chloride (**10.HCl**).




Figure S26.  $^1\text{H}$  NMR spectrum, 299.97 MHz,  $\text{CDCl}_3$ , 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-amine (**10**).




Figure S27. <sup>19</sup>F NMR spectrum, 282.23 MHz, CDCl<sub>3</sub>, 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-amine (**10**).




Figure S28. <sup>13</sup>C NMR spectrum, 75.44 MHz, CDCl<sub>3</sub>, 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-amine (**10**).






Figure S29. <sup>1</sup>H NMR spectrum, 299.97 MHz, CDCl<sub>3</sub>, *N,N'*-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)ethane-diylidenediamine (**17**).




Figure S30. <sup>19</sup>F NMR spectrum, 282.23 MHz, CDCl<sub>3</sub>, *N,N'*-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)ethane-diylidenediamine (**17**).




Figure S31. <sup>13</sup>C NMR spectrum, 75.44 MHz, CDCl<sub>3</sub>, *N,N'*-bis(3,3,4,4,5,5,6,7,7,8,8,8-tridecafluoro-octan-2-yl)ethane-diylienediamine (**17**).






Figure S32. <sup>1</sup>H NMR spectrum, 299.97 MHz, CD<sub>3</sub>OD, 1,3-bis(3,3,4,4,5,5,6,7,7,8,8,8-tridecafluoro-octan-2-yl)imidazolium chloride (**18**).






Figure S35.  $^1\text{H}$  NMR spectrum, 299.97 MHz,  $\text{CDCl}_3$ , *N,N'*-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)ethane-1,2-diamine (**19**).




Figure S36.  $^{19}\text{F}$  NMR spectrum, 282.23 MHz,  $\text{CDCl}_3$ , *N,N'*-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)ethane-1,2-diamine (**19**).




Figure S37. <sup>13</sup>C NMR spectrum, 75.44 MHz, CDCl<sub>3</sub>, *N,N'*-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)ethane-1,2-diamine (**19**).




Figure S38. <sup>1</sup>H NMR spectrum, 299.97 MHz, CD<sub>3</sub>CN, 1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)-4,5-dihydroimidazolium tetrafluoroborate (**20**).




Figure S39.  $^{19}\text{F}$  NMR spectrum, 282.23 MHz,  $\text{CD}_3\text{CN}$ , 1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)-4,5-dihydroimidazolium tetrafluoroborate (**20**).




Figure S40.  $^{13}\text{C}$  NMR spectrum, 75.44 MHz,  $\text{CD}_3\text{CN}$ , 1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)-4,5-dihydroimidazolium tetrafluoroborate (**20**).




Figure S41. <sup>1</sup>H NMR spectrum, 299.97 MHz, CD<sub>3</sub>CN, 1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)-4,5-dihydroimidazolium chloride (**21**).




Figure S42. <sup>19</sup>F NMR spectrum, 282.23 MHz, CD<sub>3</sub>OD, 1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)-4,5-dihydroimidazolium chloride (**21**).








Figure S45.  $^{19}\text{F}$  NMR spectrum, 282.23 MHz,  $\text{CD}_3\text{CN}$ , bis[1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)imidazolidin-2-ylidene]silver(I) bis(tetrafluoroborato)argentate (**23**).




Figure S46.  $^{13}\text{C}$  NMR spectrum, 75.44 MHz, acetone- $d_6$ , bis[1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)imidazolidin-2-ylidene]silver(I) bis(tetrafluoroborato)argentate (**23**).




Figure S47. <sup>1</sup>H NMR spectrum, 299.97 MHz, CDCl<sub>3</sub>, [1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)-1,3-dihydroimidazol-2-ylidene](dichloro)(3-chloropyridine)palladium(II) (**24**).




Figure S48. <sup>19</sup>F NMR spectrum, 282.23 MHz, CDCl<sub>3</sub>, [1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)-1,3-dihydroimidazol-2-ylidene](dichloro)(3-chloropyridine)palladium(II) (**24**).




Figure S49.  $^{13}\text{C}$  NMR spectrum, 75.44 MHz,  $\text{CDCl}_3$ , [1,3-bis(3,3,4,4,5,5,6,7,7,8,8,8-tridecafluoro-octan-2-yl)-1,3-dihydroimidazol-2-ylidene](dichloro)(3-chloropyridine)palladium(II) (**24**).




Figure S50.  $^1\text{H}$  NMR spectrum, 299.97 MHz,  $\text{CDCl}_3$ , [1,3-bis(3,3,4,4,5,5,6,7,7,8,8,8-tridecafluoro-octan-2-yl)imidazolidin-2-ylidene](dichloro)(3-chloropyridine)palladium(II) (**25**).




Figure S51. <sup>19</sup>F NMR spectrum, 282.23 MHz, CDCl<sub>3</sub>, [1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)imidazolidin-2-ylidene](dichloro)(3-chloropyridine)palladium(II) (**25**).




Figure S52. <sup>13</sup>C NMR spectrum, 75.44 MHz, CDCl<sub>3</sub>, [1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)imidazolidin-2-ylidene](dichloro)(3-chloropyridine)palladium(II) (**25**).




Figure S53.  $^1\text{H}$  NMR spectrum, 299.97 MHz,  $\text{CD}_3\text{CN}$ , *N*-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-yl)-*N*-[2-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-yl)ethyl]formamide (**26**).




Figure S54.  $^{19}\text{F}$  NMR spectrum, 282,23 MHz,  $\text{CD}_3\text{CN}$ , *N*-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-yl)-*N*-[2-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-yl)ethyl]formamide (**26**).




Figure S55.  $^{13}\text{C}$  NMR spectrum, 75.44 MHz,  $\text{CD}_3\text{CN}$ , *N*-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-yl)-*N*-[2-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-yl)ethyl]formamide (**26**).




Figure S56.  $^1\text{H}$  NMR spectrum, 299.97 MHz,  $\text{CDCl}_3$ , bis[1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-2-yl)imidazolidin-2-ylidene]dichloropalladium (**27**).




Figure S57. <sup>19</sup>F NMR spectrum, 282.23 MHz, CDCl<sub>3</sub>, bis[1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)-imidazolidin-2-ylidene]dichloropalladium (**27**).




Figure S58. <sup>13</sup>C NMR spectrum, 75.44 MHz, CDCl<sub>3</sub>, bis[1,3-bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octan-2-yl)-imidazolidin-2-ylidene]dichloropalladium (**27**).